Get the Stockscreener App
43.31
5.81%
-2.67
After Hours:
43.50
0.19
+0.44%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $43.31, with a volume of 44.35M.
It is down -5.81% in the last 24 hours and down -6.44% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$45.98
Open:
$44.17
24h Volume:
44.35M
Relative Volume:
3.08
Market Cap:
$88.14B
Revenue:
$47.64B
Net Income/Loss:
$5.42B
P/E Ratio:
16.22
EPS:
2.67
Net Cash Flow:
$13.09B
1W Performance:
-11.50%
1M Performance:
-6.44%
6M Performance:
-26.53%
1Y Performance:
-8.94%
1-Day Range:
$42.96
$45.51
1-Week Range:
$42.96
$49.24
52-Week Range:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
43.31 | 93.57B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
740.07 | 682.35B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.74 | 402.82B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
189.02 | 334.40B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
113.74 | 225.78B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
78.12 | 205.28B | 63.62B | 16.41B | 17.04B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - GuruFocus
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025 - Insider Monkey
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Earnings call transcript: Bristol-Myers Squibb Q2 2025 sees earnings beat but stock dips - Investing.com Canada
Bristol Myers tops revenue expectations on strength of older drugs, shares fall - MarketScreener
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - TradingView
Bristol Myers posts better-than-expected second quarter results on strength of top sellers - Bilyonaryo Business News
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic - Yahoo Finance
Bristol Myers raises guidance as Q2 results beat forecasts - The Pharma Letter
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion - Yahoo Finance
Bristol-Myers Squibb stock hits 52-week low at 43.89 USD - Investing.com Nigeria
Bristol-Myers Squibb Co reports results for the quarter ended June 30Earnings Summary - TradingView
Bristol Myers posts better-than-expected second quarter results on strength of top sellers By Reuters - Investing.com
Bristol Myers Squibb's 2025 EPS Target Revisions: A Strategic Realignment for Long-Term Growth - AInvest
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Bristol-Myers Squibb Co Surpasses Revenue Estimates with $12.3 Billion, Non-GAAP EPS of $1.46 Exceeds Expectations - GuruFocus
Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio - Investing.com Nigeria
Bristol-Myers Squibb Q2 2025 slides: Growth portfolio drives revenue, guidance raised - Investing.com Australia
Bristol-Myers Squibb earnings beat by $0.40, revenue topped estimates - Investing.com Nigeria
Latest Q2 2025 Financial Results: Bristol Myers Squibb Releases Earnings Report and Investor Call Details - Stock Titan
Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone - Benzinga
Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday - Benzinga
Bristol Myers Squibb: A Stock with Potential Amid Challenges - The Motley Fool
Bristol-Myers Squibb (BMY) Gets a Hold from Cantor Fitzgerald - The Globe and Mail
Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect - Yahoo Finance
Bain leads $300M bet on biotech developing BMS drugs - Axios
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital - PharmExec
Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income - Insider Monkey
Bain Capital, Bristol Myers Squibb launch biotech with $300M - The Business Journals
Adrenocortical Carcinoma Market Forecast upto 2034—Insights into Emerging Therapies and Market Trends | DelveInsight - GlobeNewswire Inc.
October 17th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers, Bain Capital form new company to develop immunology drugs - Reuters
Technical Bounce Expected in Bristol Myers Squibb Company Equity Right Next WeekTrade Scanner With Buy Zone Alerts Flagged - metal.it
Bristol-Myers Squibb stock unchanged as Cantor Fitzgerald maintains Neutral rating By Investing.com - Investing.com South Africa
Bristol-Myers Squibb stock unchanged as Cantor Fitzgerald maintains Neutral rating - Investing.com
BMS and Bain Capital create new company - The Pharma Letter
BMO Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail
Bain leads $300M investment in startup built on Bristol Myers immune drugs - BioPharma Dive
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients - BioSpace
4 Dead After Gunman Attacks NYC Office Building: Live Updates - New York Magazine
Bristol Myers Squibb and Bain Capital Create New Company - citybiz
10 Best and Safe Dividend Stocks to Buy Now - Insider Monkey
Bristol Myers, Bain Capital form a new biopharmaceutical company - Seeking Alpha
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
BMS and Bain Capital form new biotech company for autoimmune therapies - Investing.com Canada
Bain Capital and Bristol Myers Squibb form new biopharma company - pehub.com
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts? - TradingView
MapLight raises $373M to plot phase 2 journey for would-be rival to BMS' Cobenfy - Fierce Biotech
What institutional investors are buying Bristol Myers Squibb Company Equity Right stockAchieve breakthrough gains with smart trades - jammulinksnews.com
Should I hold or sell Bristol Myers Squibb Company stock in 2025Rapid market gains - jammulinksnews.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):